Mental Health Blogs

For those of you interested in the stock markets, one of the big stories out there today was that Lilly’s stock dropped about 3 percent today–a sizable move for a fairly stable stock. Reportedly, Lilly CEO John Lechleiter gave a speech before analysts in New York and offered little hope for how the company will fare financially in 2011 and beyond as Zyprexa and, then, Cymbalta come off-patent.

What no one has picked up on in the financial press so far is that Lechleiter also isn’t saying a thing about Lilly’s experimental compound, LY2140023, which failed a major clinical trial earlier this year. The company does have an ongoing safety study of the compound, so they are pushing ahead, but it’s likely Lilly’s revenues will take a huge hit in 2011. Unless the company has some trick up its sleeve. And it usually does.

Go to Source

Related posts:

1. Lilly Settles Mississippi Zyprexa Claims For $18.5 Million
2. Lilly Details $22 Million In Payouts To Doctor Consultants
3. Ruth Lilly, Eli Lilly Heiress, Prozac Beneficiary Dies At 94
4. Lilly Settles Zyprexa Claims With South Carolina
5. Lilly Wins Partial Zyprexa Court Victory